Alumni Ventures Group, LLC is a venture capital firm based in Manchester, New Hampshire, founded in 2013. The firm specializes in seed and early-stage investments, as well as late-stage pre-IPO opportunities, with a flexible approach that is sector and geographic agnostic. Alumni Ventures aims to provide high-quality, diversified venture portfolios to individual investors, particularly accredited alumni from top entrepreneurial schools, who may not have had access to venture capital previously. The firm focuses on backing companies that have an alumni connection and are led by established institutional investors with expertise in their respective fields. Additionally, Alumni Ventures offers focused funds that enable accredited investors to access a diverse portfolio of investments across various types, sectors, stages, and geographies.
Managing Partner, Castor Ventures and Strawberry Creek Ventures
Edward Tsai
Managing Partner
Brittney Wade
Senior Associate, Seed Fund and Doctors Innovate Fund
Drew Wandzilak
Senior Associate, Green D and Yard and Strategic Tech Fund
Sarah Worden
Venture Scout
Ray Wu
Managing Partner-Web3 / Blockchain Fund
Michael Yuann
Director of Investment Operations
Past deals in Minnesota
Civic Eagle
Venture Round in 2019
Civic Eagle, Inc. is a software company that provides a workflow solution for advocates and policy teams, enabling them to discover, analyze, and manage state and federal legislation. Founded in 2015 and based in Minnesota, Civic Eagle offers a platform called Enview that consolidates legislative information and team communications, allowing lobbyists and policy professionals to streamline their efforts without manual data entry. The platform helps users track and engage with legislation across the country, empowering policy advocates to focus on their campaigns and promote more effective democratic outcomes for their communities.
StemoniX
Series B in 2019
StemoniX Inc. is a biotechnology company specializing in stem cell technologies to enhance drug discovery and personalized medicine. Founded in 2014 and headquartered in Minneapolis, Minnesota, with an additional office in La Jolla, California, StemoniX offers a platform that focuses on the 3-D printing of stem-cell derived human tissues. This innovative approach allows for the creation of custom drug discovery models and facilitates the development of living cells in larger formats, addressing various medical conditions such as heart disease, dementia, breast cancer, autism, and ALS. The company's platform also operationalizes human induced pluripotent stem cell (iPSC) disease models for high-throughput screening, improving the research process for neurotoxicity and other drug screening efforts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.